- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05714683
Regulatory Post Marketing Surveillance (rPMS)-onderzoek naar Rybelsus (orale semaglutide) om de veiligheid en effectiviteit te evalueren bij patiënten met diabetes mellitus type 2 in de routinematige klinische praktijk in Korea
Een multicentrische, prospectieve, open-label, eenarmige, niet-interventionele, regelgevende postmarketingsurveillance (rPMS)-studie van Rybelsus® (orale semaglutide) om de veiligheid en effectiviteit te evalueren bij patiënten met diabetes mellitus type 2 in de routinematige klinische praktijk in Korea
The aim of this study is to assess the safety and effectiveness of Rybelsus initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Rybelsus as prescribed by study doctor. The study will last for about 26 weeks.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Novo Nordisk
- Telefoonnummer: (+1) 866-867-7178
- E-mail: clinicaltrials@novonordisk.com
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Adult participants with T2DM, who initiate treatment with Rybelsus under routine clinical practice in Korea.
Beschrijving
Inclusion Criteria:
- The decision to initiate treatment with commercially available Rybelsus has been made by the participant/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study
- The participant with T2DM is scheduled to start treatment with Rybelsus based on the clinical judgment of their treating physician as specified in the approved label in Korea
- Informed consent is obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study
- Male/female age greater than or equal to (>=) 19 years at the time of signing informed consent
Exclusion Criteria:
- Participants who are or have previously been on Rybelsus therapy
- Known or suspected hypersensitivity to Rybelsus, the active substance or any of the excipients
- Previous participation in this study. Participation is defined as having given informed consent in this study
- Female participant who is pregnant, breast-feeding or intends to become pregnant and is of child-bearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by Korea regulation or practice)
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Family or personal history of multiple Endocrine Neoplasia Type 2 (MEN 2) or Medullary Thyroid Carcinoma (MTC)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Participants with T2DM
All participants will be treated with Rybelsus for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by Ministry of Food and Drug Safety (MFDS). |
All participants will be treated with oral semaglutide for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS. The prescription of semaglutide will be separated from the decision to include the participant in the study.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number (Incidence) of adverse events (AEs)
Tijdsspanne: From baseline (week 0) to 26 weeks
|
Measured as count of events. |
From baseline (week 0) to 26 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number (Incidence) of hypoglycaemia Level 3 or Level 2
Tijdsspanne: From baseline (week 0) to 26 weeks
|
Hypoglycaemia Level 3 or Level 2 according to American Diabetes Association (ADA) guideline 2020 refers to: 1) Level 2: Glucose less than (<) 54 milligrams per deciliter (mg/dL) (3.0 millimoles per liter [mmol/L]); 2) Level 3: A severe event characterized by altered mental and/or physical status requiring assistance for treatment of hypoglycaemia. Measured as count of events. |
From baseline (week 0) to 26 weeks
|
|
Change in glycated haemoglobin (HbA1c)
Tijdsspanne: From baseline (week 0) to 26 weeks
|
Measured in percentage (%). |
From baseline (week 0) to 26 weeks
|
|
Participants achieving HbA1c target <7.0%
Tijdsspanne: At 26 weeks
|
Measured as count of participants (Yes/No). |
At 26 weeks
|
|
Change in fasting blood glucose (FBG)/fasting plasma glucose (FPG)
Tijdsspanne: From baseline (week 0) to 26 weeks
|
Measured in mg/dL. |
From baseline (week 0) to 26 weeks
|
|
Change in post prandial blood glucose (PPBG)/post prandial plasma glucose (PPPG)
Tijdsspanne: From baseline (week 0) to 26 weeks
|
Measured in mg/dL. |
From baseline (week 0) to 26 weeks
|
|
Change in body weight
Tijdsspanne: From baseline (week 0) to 26 weeks
|
Measured in kilogram (kg). |
From baseline (week 0) to 26 weeks
|
|
Dose of Rybelsus
Tijdsspanne: At 26 weeks
|
Measured in milligrams per day (mg/day). |
At 26 weeks
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- NN9924-4652
- U1111-1243-9500 (Andere identificatie: World Health Organization (WHO))
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .